SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candel Therapeutics is trending as investors focus on the company's progress toward a Q4 BLA submission for its prostate cancer therapy, alongside growing institutional accumulation and excitement surrounding upcoming conference presentations. Community discussion is dominated by potential buyout scenarios, strong institutional backing, and clinical data supporting the platform's ability to trigger systemic immune activation.

Paramount Skydance Corp. is a next-generation global media and entertainment company that engages in providing content creation and distribution services. It operates through the following business segments: Studios, Direct-to-Consumer, and TV Media. Its portfolio unites brands including Paramount Pictures, Paramount Television, CBS, CBS News, Nickelodeon, MTV, BET, Comedy Central, Showtime, Paramount Plus, Pluto TV, and Skydance’s Animation, Film, Television, Interactive/Games, and Sports divisions. The company is headquartered in New York, NY.

Paramount Skydance Corp. - Ordinary Shares - Class B

Paramount shares are fluctuating as investors monitor legal proceedings and public pressure to reach a settlement in the Warner Bros. Discovery merger, with community sentiment shifting toward the potential benefits of stabilizing the company's future. Retail participants remain focused on the company's efforts to navigate antitrust hurdles, with many highlighting recent calls from industry leaders and government officials to resolve the dispute out of court.

Fundrise Innovation Fund LLC operates as a non-diversified, closed-end management investment company. It invests in growing tech companies to help them expand and generate profits. The company was founded on June 7, 2021 and is headquartered in Washington, DC.

Fundrise Innovation Fund LLC. - Common Shares of Limited Liability Company Interests

Fundrise Innovation Fund 

VCX is trending as investors react to the accelerated lockup expiration date and intense market speculation regarding its private holdings in AI giants like Anthropic and OpenAI. While bulls point to the potential for significant long-term appreciation as these companies approach public markets, the community remains deeply divided, with many actively debating the fund's current valuation premium relative to its underlying net asset value.

Reddit, Inc. operates an entertainment, social networking, and news website where registered community members can submit content. The firm provides online news services where users can select and rank web content. It also offers a personalized filter on the day's story, using previous votes to determine what new things the user might like to read. The company was founded by Steven Ladd Huffman and Alexis Ohanian on June 23, 2005 and is headquartered in San Francisco, CA.

Reddit Inc. - Ordinary Shares - Class A

Reddit Inc

Reddit Inc. is trending as the stock prepares for its upcoming inclusion in the S&P 500, a milestone that has sparked intense debate among investors regarding the company's growth trajectory and future price action. Community discussions are split between bulls highlighting strong revenue growth and index-driven demand, and skeptics focusing on insider share sales, bot activity, and the company's dependence on AI licensing deals.

Memecoin on Cronos launched by the Cro Crow community

crow with knife

crow with knife is trending as the community rallies behind its multichain expansion and deflationary mechanics, positioning the project as a long-term play rather than just a meme. Investors are actively coordinating on social platforms and Discord, frequently highlighting the project's viral growth and the dedicated efforts of its global community to reach new milestones.

Uber Technologies, Inc. is a technology platform, which engages in the development and operation of technology applications, networks, and product to power movement from point A to point B. The firm offers ride services and merchants delivery service providers for meal preparation, grocery, and other delivery services. It operates through the following segments: Mobility, Delivery, and Freight. The Mobility segment refers to products that connect consumers with mobility drivers who provide rides in a variety of vehicles, such as cars, auto rickshaws, motorbikes, minibuses, and taxis. The Delivery segment offers consumers the chance to search for and discover local restaurants, order a meal, and either pick-up at the restaurant or have the meal delivered. The Freight segment focuses on connecting carriers with shippers on its platform, and gives carriers upfront, transparent pricing, and the ability to book a shipment. The company was founded by Oscar Salazar Gaitan, Travis Kalanick, and Garrett Camp in 2009 and is headquartered in San Francisco, CA.

Uber Technologies Inc

Uber is trending as investors digest quarterly results that showed solid growth and significant cash generation, alongside news of its expanded robotaxi partnership with Pony.ai to deploy autonomous vehicles in Europe. The market is actively debating the company's long-term valuation, with many users highlighting its strong free cash flow and potential for market-share dominance, while others remain skeptical about autonomous vehicle competition and short-term guidance.

Nu Holdings Ltd. is a holding company, which engages in the provision of digital banking services. The company was founded by David Vélez Osorno, Cristina Helena Zingaretti Junqueira, and Adam Edward Wible on February 26, 2016 and is headquartered in São Paulo, Brazil.

Nu Holdings Ltd - Ordinary Shares Class A

Nu Holdings Ltd

Nu Holdings is trending due to the announcement of a one billion dollar share buyback program, which investors view as a strong signal of confidence despite recent downward pressure from analyst downgrades and CFO transition concerns. The community remains largely bullish, focusing on the company's elite execution, rapid customer growth in Latin America, and potential for successful expansion into the U.S. market.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is trending as institutional investors increase their holdings in anticipation of upcoming Q2 earnings, while the community remains hyper-focused on whether the company will finally disclose concrete progress regarding its Matrix-M partnership pipeline and the stalled combination vaccine program. Discussion is dominated by speculation over a potential strategic buyout and frustration with the current management team's communication transparency.

Boston Scientific Corp. engages in the development, manufacture, and marketing of medical devices that are used in interventional medical procedures. It operates through the MedSurg and Cardiovascular segments. The MedSurg segment includes Endoscopy, Urology, and Neuromodulation. The Cardiovascular segment consists of Cardiology and Peripheral Interventions. The company was founded by John E. Abele and Pete Michael Nicholas on June 29, 1979 and is headquartered in Marlborough, MA.

Boston Scientific Corp.

Boston Scientific is currently trending as investors debate whether the recent sharp pullback is a structural breakdown or an opportunity to accumulate a high-quality name at a deep discount, with significant community attention focused on recent insider buying and speculative talk of potential M&A activity. Traders are closely monitoring key support levels and upcoming earnings as they look for signs of a technical reversal following months of downward pressure.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is trending as investors aggressively accumulate shares and call options, betting on the imminent 80th event trigger for the Phase 3 REGAL trial. The community remains deeply divided, with bulls pointing to institutional accumulation as a sign of trial success and potential buyout, while vocal skeptics argue that protocol modifications could undermine the interpretability of the final data.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$CRMD Q2 &#39;26 Earnings Results &amp; Recap

• Reported GAAP EPS of $0.33 up 13.79% YoY
• Reported revenue of $101.93M up 156.52% YoY
• CorMedix maintains full-year 2026 consolidated revenue guidance of $325 to $345 million, raises full-year adjusted EBITDA guidance to $125 to $140 million, and narrows cash OpEx guidance to $145 to $155 million.

David Martin

Ron Veres

Dr. Evil

Luckson Jeevakumar

alicia

Howard Lindzon

MISS JOANNE TRACE HAYWOOD

Blueberry

Carpediem333

Alex

Stocktwits

CorMedix Inc

 Q2 '26 Earnings Results & Recap

• Reported GAAP EPS of $0.33 up 13.79% YoY
• Reported revenue of $101.93M up 156.52% YoY
• CorMedix maintains full-year 2026 consolidated revenue guidance of $325 to $345 million, raises full-year adjusted EBITDA guidance to $125 to $140 million, and narrows cash OpEx guidance to $145 to $155 million.

This account has been verified as an official STOCKTWITS representative.

Verified Account

Stocktwits Earnings

@StocktwitsEarnings The Company signed a new multi-year commercial supply agreement for DefenCath® with a Large Dialysis Operator (LDO), expanding the company’s commercial contract footprint to include all of the top 5 providers of dialysis services in the U.S. market. The LDO has commenced ordering of DefenCath® and will begin a pilot in the third quarter this year.

steve wise

Drew Marks

Highest High

dog dog diggity dog

Vladimir Biga

CHF55

StockTwits for iOS

 The Company signed a new multi-year commercial supply agreement for DefenCath® with a Large Dialysis Operator (LDO), expanding the company’s commercial contract footprint to include all of the top 5 providers of dialysis services in the U.S. market. The LDO has commenced ordering of DefenCath® and will begin a pilot in the third quarter this year.